Physician profile
Richard M Jun
NPI 1548373236
$3,227.86
in general payments reported to CMS, 2019-2025
10 companies · $538 in 2025
The $538 reported for 2025 was more than what 85% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $76.02 · 2021: $485 · 2022: $431 · 2023: $725 · 2024: $582 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,004.97 | 2022-2025 | Infuse, Vyzulta |
| Coopervision INC. | $929.84 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $761.66 | 2020-2025 | Precision7, Precision 1, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $343.01 | 2019-2021 | |
| Allergan, INC. | $74.39 | 2022 | |
| Oyster Point Pharma, INC. | $37.48 | 2023-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $31.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.34 | 2019 | |
| Shire North American Group INC | $16.08 | 2019 | |
| Biotissue Holdings INC. | $9.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.